Jupiter Wellness Advances Clinical Pipeline of CBD-Based Topical Treatments

Jupiter Wellness Advances Clinical Pipeline of CBD-Based Topical Treatments
ACCESSWIRE
Four Indications in Clinical Development
JUPITER, FL / ACCESSWIRE / April 29, 2021 / Jupiter Wellness, Inc. (NASDAQ:JUPW), a leading developer of cannabidiol (CBD) based medical therapeutics and wellness products, today announced an update on its clinical pipeline of CBD-based therapeutic topical formulations including JW-100 for the treatment of eczema, JW-200 for skin cancer, JW-300 for burns, and JW-400 for herpes cold sores.
Commenced Patient Enrollment for Skin Cancer: Study Completion Expected Q4 2021
Jupiter's JW-200 is designed to provide action and relief in the treatment of Actinic Keratosis (AK), the most common precancer that forms on skin as a result of exposure to ultraviolet (UV) rays. The objective of this double blinded, placebo-controlled study is to evaluate the efficacy of JW-200 in both the treatment and prevention of disease, with a primary efficacy endpoint of the percentage of patients with complete clearance of AK lesions. An estimated 120 adults diagnosed with AK will be recruited, with an expected study completion date of Q4 2021.

Related Keywords

United States ,Americans ,Brian John ,Indications In Clinical Development ,Skin Cancer Foundation ,Company Investigational New Drug ,Jupiter Wellness Inc ,Drug Administration ,Nasdaq ,Four Indications ,Clinical Development ,Jupiter Wellness ,Patient Enrollment ,Skin Cancer ,Actinic Keratosis ,Recruitment Started ,First Degree Burns ,Eczema Phase ,Investigational New Drug ,Herpes Cold Sores Expected ,Private Securities Litigation Reform Act ,ஒன்றுபட்டது மாநிலங்களில் ,அமெரிக்கர்கள் ,பிரையன் ஜான் ,தோல் புற்றுநோய் அடித்தளம் ,வியாழன் ஆரோக்கியம் இன்க் ,நாஸ்டாக் ,மருத்துவ வளர்ச்சி ,வியாழன் ஆரோக்கியம் ,நோயாளி சேர்க்கை ,தோல் புற்றுநோய் ,முதல் பட்டம் தீக்காயங்கள் ,ப்ரைவேட் பத்திரங்கள் வழக்கு சீர்திருத்தம் நாடகம் ,